<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353675</url>
  </required_header>
  <id_info>
    <org_study_id>TG4010.24</org_study_id>
    <nct_id>NCT03353675</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Transgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, single arm, open label phase II study in treatment-naïve for advanced&#xD;
      stage of the disease and immunotherapy-naïve patients with advanced non-squamous NSCLC and&#xD;
      with &lt; 50% of tumor cells expressing PD-L1 by immunohistochemical (IHC) staining.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 16, 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">November 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>15 months</time_frame>
    <description>Proportion of patients whose best overall response is CR or PR using RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>15 months</time_frame>
    <description>Time from the date of the first study drug administration to the date of first documented tumor progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>15 months</time_frame>
    <description>Proportion of patients whose best overall response is either CR, PR, or SD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>27 months</time_frame>
    <description>Time from the date of first study treatment administration to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall Response (DoR)</measure>
    <time_frame>15 months</time_frame>
    <description>Time from first documented response (CR or PR) until documented disease progression or death due to lung cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Safety profile</measure>
    <time_frame>Up to 100 days after last study treatment administration</time_frame>
    <description>Incidence of all AEs, SAEs according to CTCAE v4.03.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>TG4010/Chemotherapy/Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TG4010</intervention_name>
    <description>1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks</description>
    <arm_group_label>TG4010/Chemotherapy/Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Pemetrexed/Cisplatin or Carboplatin&#xD;
Pemetrexed maintenance</description>
    <arm_group_label>TG4010/Chemotherapy/Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>360 mg IV administration every 3 weeks</description>
    <arm_group_label>TG4010/Chemotherapy/Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Principal Inclusion Criteria:&#xD;
&#xD;
          -  Female or male patients age &gt; 18 years-old&#xD;
&#xD;
          -  ECOG performance Status 0 or 1 at study entry&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Histologically confirmed non-squamous NSCLC (adenocarcinoma, large cell carcinoma,&#xD;
             undifferentiated carcinoma or other)&#xD;
&#xD;
          -  Stage IIIB-IV cancer or delayed relapse of any stage not amenable to surgery or&#xD;
             radiotherapy with curative intent.&#xD;
&#xD;
          -  PD-L1 expression by immunohistochemistry in &lt; 50% of tumor cells&#xD;
&#xD;
          -  Patients must be chemotherapy-naïve for the advanced stage of the disease. Previous&#xD;
             neoadjuvant and/or adjuvant chemotherapy is allowed for patients who successfully&#xD;
             underwent complete radical surgery and if last treatment was administered more than 12&#xD;
             months prior to the start of the study treatment.&#xD;
&#xD;
          -  At least one measurable lesion by CT scan based on RECIST 1.1 performed within 28 days&#xD;
             prior to start of study treatment&#xD;
&#xD;
          -  Adequate hematological, hepatic, and renal functions&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within 72 hours prior to the start of study drug&#xD;
&#xD;
          -  WOCBP must agree to follow instructions for method(s) of contraception for the&#xD;
             duration of treatment with study drug(s) plus 5 half-lives of study drug plus 30 days&#xD;
             for a total of 5 months posttreatment completion. Highly effective contraception are&#xD;
             defined in the protocol.&#xD;
&#xD;
          -  Men who are sexually active with WOCBP must agree to follow instructions for method(s)&#xD;
             of contraception for the duration of treatment with study drug (s) plus 5 half-lives&#xD;
             of study drug (s) plus 90 days for a total of 7 months post-treatment completion&#xD;
&#xD;
        Principal Exclusion Criteria:&#xD;
&#xD;
          -  Patients having CNS metastases&#xD;
&#xD;
          -  Patients with pericardial effusion&#xD;
&#xD;
          -  Prior exposure to cancer immunotherapy including cancer vaccines, anti-PD-1,&#xD;
             anti-PD-L1, anti-PD-L2, anti-cytotoxic T-Lymphocyte antigen- 4 antibody or any other&#xD;
             antibody or drug specifically targeting T-cell costimulation or checkpoint pathways&#xD;
&#xD;
          -  Patients with EGFR activating mutations or ALK- rearrangements leading to eligibility&#xD;
             for TKI treatment (tests mandatory)&#xD;
&#xD;
          -  Prior history of other malignancy except basal cell carcinoma of the skin, cervical&#xD;
             intra epithelial neoplasia, and other cancer curatively treated with no evidence of&#xD;
             disease for at least 3 years&#xD;
&#xD;
          -  Patients with a condition requiring systemic treatment with either corticosteroids or&#xD;
             other immunosuppressive medications within 14 days of start of study treatment&#xD;
&#xD;
          -  Patients with an active, known or suspected autoimmune disease&#xD;
&#xD;
          -  Patient with interstitial lung disease that is symptomatic or may interfere with the&#xD;
             detection or management of suspected drug-related pulmonary toxicity&#xD;
&#xD;
          -  Patients with grade ≥ 2 neuropathy&#xD;
&#xD;
          -  Signs or symptoms of infection within 14 days prior to start of study treatment or&#xD;
             active infection requiring systemic therapy&#xD;
&#xD;
          -  Positive serology for HIV or HCV; presence in the serum of the antigens HBs at&#xD;
             baseline&#xD;
&#xD;
          -  Patient with any underlying medical condition that the treating physician considers&#xD;
             might be aggravated by treatment or which is not controlled (e.g., elevated troponin&#xD;
             or creatinine, uncontrolled diabetes)&#xD;
&#xD;
          -  History of cardiovascular conditions within 12 months of enrollment&#xD;
&#xD;
          -  Left ventricular ejection fraction less than the Lower Limit of Normal as assessed by&#xD;
             echocardiography (or MUGA scan)&#xD;
&#xD;
          -  Patient with major surgery or radiotherapy within 3 weeks prior to the start of the&#xD;
             study treatment. However, prior surgery or radiation therapy aimed at local palliation&#xD;
             or attempted local disease control (except in case of thoracic radiotherapy) is&#xD;
             permitted but has to be completed 2 weeks before treatment start&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
&#xD;
          -  Patients with an organ allograft&#xD;
&#xD;
          -  Any known allergy to eggs, gentamicin or history of allergy or hypersensitivity to&#xD;
             study drug components&#xD;
&#xD;
          -  Participation in a clinical study with an investigational product within 4 weeks prior&#xD;
             to the start of the study treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Libramont</name>
      <address>
        <city>Libramont</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Créteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szekesfehervar</name>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <disposition_first_submitted>August 19, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 26, 2020</disposition_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Therapeutic Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 26, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

